Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. / Nielsen, Rune; Kankaanranta, Hannu; Bjermer, Leif; Lange, Peter; Arnetorp, Sofie; Hedegaard, Morten; Stenling, Anna; Mittmann, Nicole.

In: Respiratory Medicine, Vol. 107, No. 11, 11.2013, p. 1709-21.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Nielsen, R, Kankaanranta, H, Bjermer, L, Lange, P, Arnetorp, S, Hedegaard, M, Stenling, A & Mittmann, N 2013, 'Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries', Respiratory Medicine, vol. 107, no. 11, pp. 1709-21. https://doi.org/10.1016/j.rmed.2013.06.007

APA

Nielsen, R., Kankaanranta, H., Bjermer, L., Lange, P., Arnetorp, S., Hedegaard, M., ... Mittmann, N. (2013). Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine, 107(11), 1709-21. https://doi.org/10.1016/j.rmed.2013.06.007

Vancouver

Nielsen R, Kankaanranta H, Bjermer L, Lange P, Arnetorp S, Hedegaard M et al. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine. 2013 Nov;107(11):1709-21. https://doi.org/10.1016/j.rmed.2013.06.007

Author

Nielsen, Rune ; Kankaanranta, Hannu ; Bjermer, Leif ; Lange, Peter ; Arnetorp, Sofie ; Hedegaard, Morten ; Stenling, Anna ; Mittmann, Nicole. / Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. In: Respiratory Medicine. 2013 ; Vol. 107, No. 11. pp. 1709-21.

Bibtex

@article{fb3f315b2118469ea8871b3d0567b758,
title = "Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries",
abstract = "Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler({\circledR})+tiotropium (TIO) HandiHaler({\circledR}) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting β2-agonists (ICS/LABA).",
author = "Rune Nielsen and Hannu Kankaanranta and Leif Bjermer and Peter Lange and Sofie Arnetorp and Morten Hedegaard and Anna Stenling and Nicole Mittmann",
note = "Copyright {\circledC} 2013 Elsevier Ltd. All rights reserved.",
year = "2013",
month = "11",
doi = "10.1016/j.rmed.2013.06.007",
language = "English",
volume = "107",
pages = "1709--21",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "Elsevier",
number = "11",

}

RIS

TY - JOUR

T1 - Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries

AU - Nielsen, Rune

AU - Kankaanranta, Hannu

AU - Bjermer, Leif

AU - Lange, Peter

AU - Arnetorp, Sofie

AU - Hedegaard, Morten

AU - Stenling, Anna

AU - Mittmann, Nicole

N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.

PY - 2013/11

Y1 - 2013/11

N2 - Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler(®)+tiotropium (TIO) HandiHaler(®) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting β2-agonists (ICS/LABA).

AB - Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler(®)+tiotropium (TIO) HandiHaler(®) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting β2-agonists (ICS/LABA).

U2 - 10.1016/j.rmed.2013.06.007

DO - 10.1016/j.rmed.2013.06.007

M3 - Journal article

C2 - 23856511

VL - 107

SP - 1709

EP - 1721

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 11

ER -

ID: 105585066